<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83317">
  <stage>Registered</stage>
  <submitdate>3/11/2008</submitdate>
  <approvaldate>21/11/2008</approvaldate>
  <actrnumber>ACTRN12608000588392</actrnumber>
  <trial_identification>
    <studytitle>A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer</studytitle>
    <scientifictitle>A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy to improve progression free survival in advanced non-small cell lung cancer</scientifictitle>
    <utrn />
    <trialacronym>NITRO</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced non-small cell lung cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The addition of topical Nitroglycerin (patch) to standard chemotherapy (standard chemotherapy involves a combination of cisplatin or carboplatin with one of the following drugs - vinorelbine, paclitaxel, pemetrexed or gemcitabine). Each patient's specific treatment regime will be determined by the participant's doctor. Nitroglycerin is administered as a 25mg patch for 12 hours each day for 2 days before, the day of, and for two days after each chemotherapy injection. Treatment with the chemotherapy and Nitroglycerin will last for 6 treatment cycles (each cycle lasts for 3 weeks)</interventions>
    <comparator>Standard Chemotherapy standard chemotherapy involves a combination of cisplatin or carboplatin with one of the following drugs - vinorelbine, paclitaxel, pemetrexed or gemcitabine. Each patient's specific treatment regime will be determined by the participant's doctor.Treatment with the chemotherapy will last for 6 treatment cycles (each cycle lasts for 3 weeks)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival which is measured by regular CT (computerised tomography) scans prior to treatment, every six weeks during chemotherapy, and every two months after chemotherapy until the lung cancer has progressed</outcome>
      <timepoint>After 460 progression events have occurred over all of the participants in the study (after 460 patients have shown progression of their lung cancer)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival which will be measured by regular visits to the hospital throughout chemotherapy, and then visits every two months after chemotherapy.</outcome>
      <timepoint>At the end of the study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Confirmed diagnosis of stage III or IV non-small cell lung cancer
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Adequate bone marrow, kidney and liver function
Radiotherapy completed at least 1 week before randomisation
Patient is willing and able to comply with protocol requirements
Patient has completed quality of life questionnaires or is unable to complete due to illiteracy, language or limited vision
Female patients of childbearing potential must be willing to use adequate contraception
Plan to start chemotherapy within 8 days of randomisation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Untreated brain or meningeal metastases
Life expectancy less than 3 months
Any prior systemic therapy for advanced non-small cell lung cancer
History of previous or concomitant malignancies at other sites within the last 5 years
On nitrates, dihydroergotamine or phosphodiesterase inhibitors
History of allergic disease or reactions likely to be exacerbated by nitroglycerin
Uncontrolled cardiovascular disease
Other concomitant medical problems which would limit compliance with the study procedures or expose the patient to unacceptable risk
Active and uncontrolled infections</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Enrolment will be performed at the hospital and randomisation will be performed centrally at the University of Sydney Clinical Trials Centre by computer</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>15/05/2009</anticipatedstartdate>
    <actualstartdate>15/05/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>14/04/2014</actualenddate>
    <samplesize>500</samplesize>
    <actualsamplesize>372</actualsamplesize>
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,QLD,SA,WA,TAS</recruitmentstate>
    <postcode>2042</postcode>
    <postcode>2031</postcode>
    <postcode>2139</postcode>
    <postcode>2170</postcode>
    <postcode>2340</postcode>
    <postcode>2200</postcode>
    <postcode>2450</postcode>
    <postcode>2250</postcode>
    <postcode>2480</postcode>
    <postcode>2485</postcode>
    <postcode>2747</postcode>
    <postcode>2350</postcode>
    <postcode>2444</postcode>
    <postcode>2305</postcode>
    <postcode>3065</postcode>
    <postcode>3181</postcode>
    <postcode>3550</postcode>
    <postcode>3220</postcode>
    <postcode>3280</postcode>
    <postcode>4814</postcode>
    <postcode>4870</postcode>
    <postcode>4560</postcode>
    <postcode>4032</postcode>
    <postcode>4033</postcode>
    <postcode>5011</postcode>
    <postcode>6009</postcode>
    <postcode>6000</postcode>
    <postcode>7000</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>Locked Bag 77
Camperdown NSW 1450</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>WA Cancer Council</fundingname>
      <fundingaddress>46 Ventnor Avenue
West Perth 6005 WA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>QLD Cancer Council</fundingname>
      <fundingaddress>553 Gregory Terrace
Fortitude Valley Qld 4006</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>NSW Cancer Council</fundingname>
      <fundingaddress>153 Dowling Street 
Woolloomooloo, NSW 2011</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Cancer Australia</fundingname>
      <fundingaddress>Level 14, 300 Elizabeth Street, SURRY HILLS NSW 2010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Australasian Lung Cancer Trials Group</othercollaboratorname>
      <othercollaboratoraddress>PO Box 847
Lutwyche QLD 4030</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the efficacy of adding the drug, nitroglycerin, to first line chemotherapy for advanced non-small cell lung cancer. 

Who is it for?
You may be eligible to join this study if you are 18 years or above and have a confirmed diagnosis of stage III or IV non-small cell lung cancer. Radiotherapy should have been completed at least one week before commencing treatment in this study. 

Trial details 
Participants in this trial will be randomly (by chance) allocated to one of two groups. Both groups undergo 6 x 3 week treatment cycles of standard chemotherapy determined by their doctor. In addition, participants in group one will receive nitroglycerin administered as a 25mg patch for 12 hours each day for 2 days before, the day of, and for two days after each chemotherapy injection. 

Participants will undergo regular visits to the hospital and undergo CT scans prior to treatment, every six weeks during chemotherapy, and every two months after chemotherapy until the lung cancer has progressed. This will help determine which treatment is more effective in terms of progression-free survival and overall survival.</summary>
    <trialwebsite />
    <publication>A. Davidson, A.-S. Veillard, A. Tognela, M. M. K. Chan, B. G. M. Hughes, M. Boyer, K. Briscoe, S. Begbie, E. Abdi, C. Crombie, J. Long, A. Boyce, C. R. Lewis, S. Varma, A. Broad, N. Muljadi, S. Chinchen, D. Espinoza, X. Coskinas, N. Pavlakis, M. Millward, and M. R. Stockler on behalf of the Australasian Lung cancer Trials Group (ALTG). A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. Ann Oncol (2015) 26 (11): 2280-2286 first published online September 7, 2015</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NSW Cancer Institute Ethics Committee</ethicname>
      <ethicaddress>PO Box 41
Alexandria NSW 1435</ethicaddress>
      <ethicapprovaldate>9/10/2008</ethicapprovaldate>
      <hrec>2008C/08/059</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney Local Health District HREC (RPAH ZONE)</ethicname>
      <ethicaddress>Research Development Office
Royal Prince Alfred Hospital
Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate>14/10/2013</ethicapprovaldate>
      <hrec>X13-0165 &amp; HREC/13/RPAH/418</hrec>
      <ethicsubmitdate>9/10/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Andrew Davidson</name>
      <address>Medical Oncology
Royal Perth Hospital
Wellington Street
Perth WA 6000</address>
      <phone>+61 8 9224 2334</phone>
      <fax>+61 8 9224 3126</fax>
      <email>andrew.davidson@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Nitro trial coordinator / data manager</name>
      <address>National Health and Medical Research Centre (NHMRC) Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>nitro@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Chinchen</name>
      <address>NHMRC Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>nitro@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Andrew Davidson</name>
      <address>Royal Perth Hospital
Medical Oncology
Wellington St, Perth, WA 6000</address>
      <phone>+61 8 9224 2334</phone>
      <fax />
      <email>andrew.davidson@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>